Viking
Viking Therapeutics Shares Crash After Obesity Pill VK2735 Delivers 12% Weight Loss, But Side Effects and Discontinuations Raise Concerns
Viking Therapeutics; VK2735; obesity pill; weight loss; clinical trial; stock crash; side effects; adverse events; gastrointestinal; drug efficacy
High Drop-Out Rate Clouds Viking Therapeutics’ Oral Weight Loss Drug Trial Results
Viking Therapeutics; oral obesity drug; VK2735; high drop-out rate; weight loss data; clinical trial; treatment discontinuations
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations
Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials
Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition